Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Horizon Discovery introduces predesigned synthetic sgRNAs to streamline CRISPR gene editing workflows


Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company's Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.

Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex, difficult-to-edit cell types and experimental models. The synthetic sgRNAs have been designed using Horizon's proprietary algorithm to maximize the likelihood of functionally knocking out the gene(s) of interest while minimizing off-target effects.

These predesigned synthetic sgRNAs, when paired with Cas9 mRNA or Cas9 protein, allow researchers to perform DNA-free gene editing in a new one-part format thereby streamlining their gene editing workflows, without the potential for nuclease or guide integration into the cell's genome. They can also be paired with expressed formats such as Cas9 integrated cell lines, which is ideal for high-throughput library screening.

The release of predesigned sgRNA expands Horizon's Edit-R platform. Library collections of sgRNAs, from common gene families up to the entire genome, are available to support large-scale screening applications. The Company will continue to provide its CRISPR design tool, where customers can design custom guide RNA to edit a specific region within a DNA transcript or input their own guide RNA target sequence to generate ready-to-use sgRNA.

Ryan Donnelly, Product Manager, Horizon Discovery, said: "Previously, Horizon had only offered synthetic sgRNAs through the CRISPR Design tool. Providing predesigned synthetic sgRNAs guarantees editing the gene of interest, and gives researchers a more convenient option for gene knockout experiments. For those that require site-specific editing, are working in unique organisms, or use alternative editing nucleases; our CRISPR design tool is still available."

For further information on Horizon's Edit-R predesigned synthetic sgRNA, click here.


These press releases may also interest you

at 07:35
The Real Brokerage Inc. , the fastest-growing, publicly traded real estate brokerage, today announced that The Property Shop, led by Season Ware, has joined the company under Real's Private Label program. Fort Worth's largest independent brokerage,...

at 07:35
Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates....

at 07:34
UK-headquartered, global Identity and Access Management (IAM) specialist, ProofID has won the Judge's Award for Global Ambition at the Northern Tech Awards held at Manchester Cathedral. The company won the award in recognition of its expansion in the...

at 07:30
Sphere Entertainment Co. ("Sphere Entertainment" or the "Company") today reported financial results for the fiscal third quarter ended March 31, 2024....

at 07:30
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and...

at 07:05
Dentalcorp Holdings Ltd. ("Dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced its financial and operating results for the first quarter ended March 31, 2024. All...



News published on and distributed by: